Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin for the Treatment of Sepsis & Septic Shock
DRKS00025884Phase 2Recruiting
- Sponsor
- Friedrich Schiller University Jena
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of epirubicin in septic shock and sepsis (4 arms), sponsored by Friedrich Schiller University Jena. Started Feb 2022; status: recruiting.
02
Drugs
epirubicin
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on DRKS00025884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025884.